Cargando…
Ethics of a partially effective dengue vaccine: Lessons from the Philippines
Dengvaxia, a chimeric yellow fever tetravalent dengue vaccine developed by SanofiPasteur is widely licensed in dengue-endemic countries. In a large cohort study Dengvaxia was found to partially protect children who had prior dengue virus (DENV) infections but sensitized seronegative children to brea...
Autores principales: | Halstead, Scott B., Katzelnick, Leah C., Russell, Philip K., Markoff, Lewis, Aguiar, Maira, Dans, Leonila R., Dans, Antonio L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347470/ https://www.ncbi.nlm.nih.gov/pubmed/32654899 http://dx.doi.org/10.1016/j.vaccine.2020.06.079 |
Ejemplares similares
-
Communicating COVID-19 vaccines: lessons from the dengue vaccine controversy in the Philippines
por: Lasco, Gideon, et al.
Publicado: (2021) -
The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries
por: Aguiar, Maíra, et al.
Publicado: (2016) -
Clinical presentations and outcomes of Filipino juvenile systemic lupus erythematosus
por: Gulay, Carien B, et al.
Publicado: (2011) -
Editorial: Connecting patient care and clinical epidemiology: The anniversary of the key concepts in clinical epidemiology series
por: van Amelsvoort, Ludo, et al.
Publicado: (2022) -
More Dengue, More Questions
por: Halstead, Scott B.
Publicado: (2005)